Effects of cromolyn oral inhalation: A Synthesis of Findings from 21 Studies
- Home
- Effects of cromolyn oral inhalation
This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of cromolyn oral inhalation: A Synthesis of Findings from 21 Studies", please consult your doctor.
For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
Major Research Findings
Cromolyn sodium inhalation is a medication used to treat asthma, and some studies have shown its effectiveness in improving asthma symptoms. 8 found that children who started using cromolyn sodium inhalation within two years of asthma onset had improved long-term outcomes. This improvement was particularly noticeable in children with severe asthma. Additionally, 10 showed that in patients with severe asthma who did not respond to high doses of inhaled corticosteroids, inhaling nebulized cromolyn sodium helped improve their symptoms. A novel formulation of inhaled cromolyn sodium (PA101), delivered via a high-efficiency eFlow nebulizer, was found to be safe and effective in reducing cough symptoms in patients with idiopathic pulmonary fibrosis (IPF) in 1 .
Benefits and Risks
Benefits Summary
Cromolyn sodium inhalation has been shown to be effective in improving asthma symptoms. 8 found that children who started using cromolyn sodium inhalation within two years of asthma onset had improved long-term outcomes. This improvement was particularly noticeable in children with severe asthma. 10 demonstrated that in patients with severe asthma who did not respond to high doses of inhaled corticosteroids, inhaling nebulized cromolyn sodium helped improve their symptoms. Moreover, 1 found that a novel formulation of inhaled cromolyn sodium (PA101), delivered via a high-efficiency eFlow nebulizer, was safe and effective in reducing cough symptoms in patients with idiopathic pulmonary fibrosis (IPF).
Risks Summary
Cromolyn sodium inhalation is generally considered safe, but side effects like cough, taste changes, and nosebleeds have been reported. 10 reported instances of cough and other side effects occurring when patients inhaled nebulized cromolyn sodium.
Comparison Between Studies
Similarities Between Studies
Multiple studies have shown the effectiveness of cromolyn sodium inhalation in improving asthma symptoms. 8 and 10 demonstrated the benefits of cromolyn sodium inhalation in children and adults with asthma, respectively. 1 showed that cromolyn sodium inhalation helped reduce cough symptoms in patients with idiopathic pulmonary fibrosis (IPF).
Differences Between Studies
Due to variations in the targeted diseases, age groups, and formulations used, a direct comparison between studies is not straightforward. 8 focused on children with asthma, while 10 focused on adults with severe asthma. Furthermore, 1 studied patients with idiopathic pulmonary fibrosis (IPF) and used a novel formulation of cromolyn sodium.
Consistency and Contradictions in Results
Multiple studies demonstrate the effectiveness of cromolyn sodium inhalation in improving asthma symptoms, indicating consistent findings. However, 10 showed that cromolyn sodium inhalation was beneficial in patients with severe asthma who had not responded to high doses of inhaled corticosteroids, which differs from other findings.
Implications for Real-World Application
Cromolyn sodium inhalation has shown effectiveness in improving asthma symptoms, but it is important to remember that it may not be effective for everyone, and side effects are possible. Therefore, it is essential to consult with a doctor and receive appropriate treatment. Additionally, starting treatment with cromolyn sodium inhalation early, within two years of asthma onset, could improve long-term outcomes. 8
Limitations of Current Research
Research on cromolyn sodium inhalation is still ongoing. Further research is needed to understand its effectiveness in patients with severe asthma and its long-term safety. Furthermore, due to variations in patient demographics and formulations used across studies, comparing results can be challenging.
Directions for Future Research
Future research on cromolyn sodium inhalation should focus on understanding its effectiveness and long-term safety in patients with severe asthma. Additionally, research is needed to compare the effectiveness of different formulations and methods of administration to determine the best treatment options for patients.
Conclusion
Cromolyn sodium inhalation is a medication that has shown potential benefits in improving asthma symptoms, but it is important to remember that not everyone will respond to it and side effects are possible. It is vital to consult with a doctor to determine if this treatment is suitable for you and to receive appropriate medical management. If you experience asthma symptoms, consult with a doctor as soon as possible.
Benefit Keywords
Risk Keywords
Article Type
Author: BirringSurinder S, WijsenbeekMarlies S, AgrawalSanjay, van den BergJan W K, StoneHelen, MaherToby M, TutuncuAhmet, MoriceAlyn H
Language : English
Author: WindtRoland, GlaeskeGerd
Language : English
Author:
Language : English
Language : English
Author: LechelerJosef, PfannebeckerBernhard, NguyenDuc Tung, PetzoldUrsula, MunzelUllrich, KremerHans-Joachim, MausJoachim
Language : English
Author: MoonHee, ChoiHyun Ho, LeeJi Yun, MoonHyo Jin, SimSang Soo, KimChang Jong
Language : English
Author: KaditisAthanasios G, WinnieGlenna, SyrogiannopoulosGeorge A
Language : English
Author: YoshiharaS, KannoN, YamadaY, OnoM, FukudaN, NumataM, AbeT, ArisakaO
Language : English
Language : English
Author: SanoYasuyuki, AdachiMitsuru, KiuchiTakahiro, MiyamotoTerumasa
Language : English
As-needed inhaled beta2-adrenoceptor agonists in moderate-to-severe asthma: current recommendations.
Author: CockcroftDonald W
Language : English
Author: BisgaardHans, AllenDavid, MilanowskiJanusz, KalevIlia, WillitsLisa, DaviesPatricia
Language : English
Author: HadleyJames A
Language : English
Author: JaffeAdam, Balfour-LynnIan M
Language : English
Author: KnorrB, FranchiL M, BisgaardH, VermeulenJ H, LeSouefP, SantanelloN, MicheleT M, ReissT F, NguyenH H, BrattonD L
Language : English
Author: SchatzM
Language : English
Author: WiegandL, MendeC N, ZaidelG, ZwillichC W, PetrocellaV J, YanceyS W, RickardK A
Language : English
Author: ReijonenT M, KorppiM
Language : English
Author: SchatzM, ZeigerR S, HardenK, HoffmanC C, ChilingarL, PetittiD
Language : English
Author: IkegamiK, HataH, FuchigamiJ, TanakaK, KohjimotoY, UchidaS, TasakaK
Language : English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.